International Journal of Hematology

, Volume 96, Issue 1, pp 74–83

Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low–intermediate risk, aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508

  • Yoshitoyo Kagami
  • Kuniaki Itoh
  • Kensei Tobinai
  • Haruhiko Fukuda
  • Kiyoshi Mukai
  • Takaaki Chou
  • Chikara Mikuni
  • Tomohiro Kinoshita
  • Noriyasu Fukushima
  • Yoshio Kiyama
  • Takayo Suzuki
  • Tsuneo Sasaki
  • Yuko Watanabe
  • Kunihiro Tsukasaki
  • Tomomitsu Hotta
  • Masanori Shimoyama
  • Michinori Ogura
  • The members of the Lymphoma Study Group of the Japan Clinical Oncology Group
Original Article

DOI: 10.1007/s12185-012-1101-2

Cite this article as:
Kagami, Y., Itoh, K., Tobinai, K. et al. Int J Hematol (2012) 96: 74. doi:10.1007/s12185-012-1101-2

Abstract

The regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone, known as CHOP therapy, has been established as the standard treatment for aggressive non-Hodgkin’s lymphoma (NHL). Although patients categorized as low (L) and low–intermediate (L–I) risk using the International Prognostic Index have favorable prognoses in Western countries, the efficacy and safety of CHOP therapy has not been prospectively evaluated in Japan. We conducted a phase II study of CHOP in L and L–I risk Japanese patients, evaluating overall survival (OS) as the primary endpoint. A total of 213 patients were enrolled and treated with eight courses of CHOP. Efficacy was evaluated in 168 eligible patients (L risk, 87; L–I risk, 81). Five-year OS rates in all eligible, L, and L–I risk patients were 68 % [95 % confidence interval (CI): 61–76 %], 73 % (95 % CI: 63–82 %), and 64 % (95 % CI: 53–74 %), respectively. The major toxicity observed was grade 4 neutropenia (64 %). Grade 4 non-hematological toxicities were observed as follows: one case each of paralytic ileus, convulsions, hypoxemia due to interstitial pneumonia, and reactivated fulminant hepatitis B. These results show reasonable efficacy and safety of the CHOP regimen in Japanese patients with lower risk aggressive NHL (UMIN-CTR Number C000000053).

Keywords

Clinical trialAggressive lymphomaChemotherapyCHOP

Copyright information

© The Japanese Society of Hematology 2012

Authors and Affiliations

  • Yoshitoyo Kagami
    • 1
    • 15
  • Kuniaki Itoh
    • 2
  • Kensei Tobinai
    • 3
  • Haruhiko Fukuda
    • 4
  • Kiyoshi Mukai
    • 5
    • 16
  • Takaaki Chou
    • 6
  • Chikara Mikuni
    • 7
    • 17
  • Tomohiro Kinoshita
    • 8
    • 18
  • Noriyasu Fukushima
    • 9
  • Yoshio Kiyama
    • 10
  • Takayo Suzuki
    • 11
  • Tsuneo Sasaki
    • 12
  • Yuko Watanabe
    • 4
  • Kunihiro Tsukasaki
    • 13
  • Tomomitsu Hotta
    • 14
    • 19
  • Masanori Shimoyama
    • 3
    • 20
  • Michinori Ogura
    • 1
    • 21
  • The members of the Lymphoma Study Group of the Japan Clinical Oncology Group
  1. 1.Department of Hematology and ChemotherapyAichi Cancer Center HospitalNagoyaJapan
  2. 2.Division of Hematology and OncologyNational Cancer Center Hospital EastKashiwaJapan
  3. 3.Department of Hematology, and Hematopoietic Stem Cell TransplantationNational Cancer Center HospitalTokyoJapan
  4. 4.JCOG Data Center, Center for Cancer Control and Information ServicesNational Cancer CenterTokyoJapan
  5. 5.Department of Clinical PathologyTokyo Medical UniversityTokyoJapan
  6. 6.Department of Internal MedicineNiigata Cancer Center HospitalNiigataJapan
  7. 7.Department of HematologyHokkaido Cancer CenterSapporoJapan
  8. 8.Department of Hematology and OncologyNagoya University Graduate School of MedicineNagoyaJapan
  9. 9.Division of Hematology, Department of Internal Medicine, Faculty of MedicineSaga UniversitySagaJapan
  10. 10.Department of HematologySapporo Hokuyu HospitalSapporoJapan
  11. 11.Division of HematologyShiga Medical Center for AdultsMoriyamaJapan
  12. 12.Department of ChemotherapyTokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalTokyoJapan
  13. 13.Molecular Medicine Unit and Hematology, Atomic Bomb Disease InstituteNagasaki University Graduate School of Biomedical SciencesNagasakiJapan
  14. 14.Department of Hematology and OncologyTokai UniversityIseharaJapan
  15. 15.Department of HematologyToyota Kosei HospitalToyotaJapan
  16. 16.Division of PathologySaiseikai Central HospitalTokyoJapan
  17. 17.Sapporo Yuushoukan HospitalSapporoJapan
  18. 18.Department of Hematology and Cell-therapyAichi Cancer Center HospitalNagoyaJapan
  19. 19.National Cancer CenterTokyoJapan
  20. 20.JCOG Data CenterCenter for Cancer Control and Information Services, National Cancer CenterTokyoJapan
  21. 21.Department of Hematology and OncologyNagoya Daini Red Cross HospitalNagoyaJapan